Top news of the day from across the health care industry.
On Tuesday, GlaxoSmithKline (GSK) announced positive results from its clinical trial testing the experimental drug dostarlimab in women with recurrent or advanced endometrial cancer, Reuters reported. According to the article, data from the GARNET study showed that dostarlimab demonstrated clinically meaningful and durable response rates when used to treat certain types of tumors. GSK said it would apply for marketing approval for dostarlimab by the end of 2019, the article reported.
A new study published in The Lancet Psychiatry indicates that consuming high-potency cannabis on a daily basis may increase the risk of psychosis later on, NPR reported. According to the article, the study identified 901 individuals who were diagnosed with their first episode of psychosis between May 2010 and April 2015 at a mental health facility and compared these individuals’ habits, such as use of marijuana, with a control group. The findings showed that those who used pot daily were 3 times more likely to have a psychotic episode compared with someone who never used the drug, the article reported.
A World Health Organization panel of experts said gene editing for reproductive purposes is “irresponsible” and called for a database of scientists working on gene editing, The Associated Press reported. According to the article, the experts said in a statement that it is irresponsible for anyone to proceed with making gene-edited babies since DNA changes could be passed down to future generations. However, the organization did not suggest a ban on such research, even though an international group of scientists recently called for a temporary ban on gene-edited babies, the article reported.